> Details

Ulinici, Mariana; Suljič, Alen; Poggianella, Monica; Milan Bonotto, Rafaela; Resman Rus, Katarina; Paraschiv, Angela; Bonetti, Amedeo Marco; Todiras, Mihail; Corlateanu, Alexandru; Groppa, Stanislav; Ceban, Emil; Petrovec, Miroslav; Marcello, Alessandro

Characterisation of the Antibody Response in Sinopharm (BBIBP-CorV) Recipients and COVID-19 Convalescent Sera from the Republic of Moldova

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Characterisation of the Antibody Response in Sinopharm (BBIBP-CorV) Recipients and COVID-19 Convalescent Sera from the Republic of Moldova
  • Contributor: Ulinici, Mariana; Suljič, Alen; Poggianella, Monica; Milan Bonotto, Rafaela; Resman Rus, Katarina; Paraschiv, Angela; Bonetti, Amedeo Marco; Todiras, Mihail; Corlateanu, Alexandru; Groppa, Stanislav; Ceban, Emil; Petrovec, Miroslav; Marcello, Alessandro
  • Published: MDPI AG, 2023
  • Published in: Vaccines, 11 (2023) 3, Seite 637
  • Language: English
  • DOI: 10.3390/vaccines11030637
  • ISSN: 2076-393X
  • Keywords: Pharmacology (medical) ; Infectious Diseases ; Drug Discovery ; Pharmacology ; Immunology
  • Origination:
  • Footnote:
  • Description: <jats:p>The early availability of effective vaccines against SARS-CoV-2, the aetiologic cause of COVID-19, has been at the cornerstone of the global recovery from the pandemic. This study aimed to assess the antispike RBD IgG antibody titres and neutralisation potential of COVID-19 convalescent plasma and the sera of Moldovan adults vaccinated with the Sinopharm BBIBP-CorV vaccine. An IgG ELISA with recombinant SARS-CoV-2 spike RBD and two pseudovirus-based neutralisation assays have been developed to evaluate neutralising antibodies against SARS-CoV-2 in biosafety level 2 containment facilities. A significant moderate correlation was observed between IgG titres and the overall neutralising levels for each neutralisation assay (ρ = 0.64, p &lt; 0.001; ρ = 0.52, p &lt; 0.001). A separate analysis of convalescent and vaccinated individuals showed a higher correlation of neutralising and IgG titres in convalescent individuals (ρ = 0.68, p &lt; 0.001, ρ = 0.45, p &lt; 0.001) compared with vaccinated individuals (ρ = 0.58, p &lt; 0.001; ρ = 0.53, p &lt; 0.001). It can be concluded that individuals who recovered from infection developed higher levels of antispike RBD IgG antibodies. In comparison, the Sinopharm-vaccinated individuals produced higher levels of neutralising antibodies than convalescent plasma.</jats:p>
  • Access State: Open Access